

AGM presentation November 2020

Michael Winlo – MD & CEO

ASX:EMD

myriad data.
individual care.

SAY IT!

Emyria

(em-meer-reeuh)

Derived from 'Myriad': Noun: an indefinitely great number of persons or things.

Adjective: of an indefinitely great number; innumerable.

Disclaimer and notices

This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any jurisdiction. This presentation contains general information only and does not consider the investment objectives, financial situation and needs of individual investors. Investors should make their own independent assessment of the information in this presentation and obtain their own independent advice from a qualified financial adviser having regard to their personal objectives, financial situation and needs before taking any action. No representation or warranty, express or implied, is made as to the accuracy, completeness, reliability or adequacy of any statements, estimates, opinions or other information, or the reasonableness of any assumption or other statement, contained in this presentation. Nor is any representation or warranty (express or implied) given as to the accuracy, completeness, likelihood of achievement or reasonableness of any forecasts, prospective statements or returns contained in this presentation. Such forecasts, prospective statements or returns are by their nature subject to significant uncertainties and contingencies, many of which are outside the control of Emyria. To the maximum extent permitted by law, Emyria and its related bodies corporate, directors, officers, employees, advisers and agents disclaim all liability and responsibility (including without limitation any liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use or reliance on anything contained in, or omitted from, this presentation. An investment in Emyria securities should be considered speculative and is subject to investment and other known and unknown risks, some of which are beyond the control of Emyria. Emyria does not guarantee any rate of return or the absolute or relative investment performance of Emyria securities. The distribution of this presentation including in jurisdictions outside Australia, may be restricted by law. Any person who receives this presentation must seek advice on and observe any such restrictions.

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of Emyria and certain of the plans and objectives of Emyria with respect to these items. These forward-looking statements are not historical facts but rather are based on Emyria's current expectations, estimates and projections about the industry in which Emyria operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Emyria, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Emyria cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Emyria only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Emyria will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Funding history & milestones in first 9 months






History

- Listed on the ASX, 12 February 2020 (ticker: EMD)
- Last reported cash position (Q3, 2020): **\$4.2m**
 - **+ \$954,000** R&D refund (02 Nov 2020)
- Market cap: **\$16.7m** (12 Nov 20)
- Shares on issue **211.4m**
- Options on issue **18.3m** (strike \$0.45)


Milestones

- **\$1m+** total contract value of **data deals**
- Unique insights a source of IP for Emyria
- **3,000+** patients referred to Emerald Clinics
- **UK partnership** (Sapphire Medical)
- Developing unique technology IP
 - Class 1 TGA registration for Openly
 - Strategic partnership with Mt Sinai

Experienced board with drug development and tech focus

Key Person	Role	Previous Experience
	Dr Stewart Washer Chairman & Founder	Cynata (ASX:CYP) – stem cells Orthocell (ASX:OCC) – regenerative medicine Botanix (ASX:BOT) – CBD (synthetic) for topical and antimicrobial use AusCann (ASX:AC8) – hard capsule cannabinoid medicines Zelira (ASX:ZLD) – cannabinoid clinical development
	Dr Michael Winlo Managing Director	Medical doctor Complex data analysis (Palantir – a Peter Thiel founded company based in Silicon Valley) Director and ex-CEO at Linear Clinical Research MBA from Stanford University Graduate School of Business
	Dr Alistair Vickery Chief Medical Officer & Director	Specialist general practitioner with >30 years' experience Associate Professor of Primary Health Care at University of Western Australia Deputy Chair of the Postgraduate Medical Council of WA Chair of Black Swan Health, one of the largest primary health care service
	Matt Callahan Non-Executive Director & Founder	Founder of Botanix Pharmaceuticals (ASX:BOT), iCeutica Inc. and Orthocell (ASX:OCC) Successfully developed 4 products through FDA approval. More than 20 years' legal, intellectual property and investment management experience
	Professor Sir John Tooke Independent Non-Executive Director	Senior Independent Director, BUPA Chile Chair of Collaboration for the Advancement of Sustainable Medical Innovation (CASMI), UCL Sir Tooke was Head of the School of Life and Medical Sciences at University College London (UCL) Immediate past President of the Academy of Medical Sciences in the Previous member of Google DeepMind Health's Independent Review Board. Leading advisor to the UK Government regarding health policy Knighted in the United Kingdom in the 2007 New Year Honours for Services to Medicine.


Traditional drug development



10-20 years | ~\$2.6 billion | 95% failure rate

Sources: Agres T. New Life for Old Drugs. Drug Discovery and Development. July 29, 2011. Accessible at: <http://www.dddmag.com/articles/2011/07/new-life-old-drugs>
Mullin R. Tufts Study Finds Big Rise in Cost of Drug Development. Nov. 20, 2014. Accessible at: <http://cen.acs.org/articles/92/web/2014/11/Tufts-Study-Finds-Big-Rise.html>

Real world evidence (RWE) *accelerates drug registration*



Emyria

Care

Provides:

- Access to patients with unmet needs
- Safe provision of new treatments by experienced care team
- Continuous safety and efficacy monitoring


Emyria

Data

Provides:

- Rapid indication insights leading to faster drug registration
- Strategic trial design using real-world patient data
- Support for payment coverage decisions
- Discovery of novel therapies

RWE *saves time and costs* in drug registration




RWE can save between \$100m and \$1b per drug

Sources:


Hughs B. Kessler M. McDonnell A. Breaking New Ground with RWE Accessible at: https://www.iqvia.com/-/media/quintilesims/pdfs/qims_breaking_new_ground_with_rwe_whitepaper.pdf

Why registration matters

Special Access Scheme (eg. all cannabinoid medicines in Aus)



Registered medicines




Registered medicines provide:
Greater patient access
Faster access for patients
Lower out-of-pocket patient costs

Sources:

<https://www.tga.gov.au/form/special-access-scheme>


How Emyria *accelerates drug registration*



Emyria provides care for patients with unmet medical needs. Collectively, this patient group represents a large proportion of health costs and a group motivated to access new care models and treatments.

Emyria's data platform generates unique and valuable data. Emyria data can be used as clinical evidence to help answer what treatments are working, for whom and at what dose to support formal drug registration.

Emyria successes to date



- TGA registration as a medical device
- Partnership with Mt Sinai
- Unique, contactless vital sign technology integrated

Creates

Accelerates

Emyria


Care

Emyria

Data

Drug registration

Informs





Emyria **elevates care** for patients
with unmet medical needs

We support unmet needs with high cost burden

Core unmet need (% of Emyria patients)	Size of patient population in Australia	Australian health system costs	Notes	References
Chronic pain (~60%)	3.37 million	\$12.64 billion	44.6% of patients living with chronic pain also experience depression or anxiety	https:// www.painaustralia.org.au/ about-pain/painful-facts
Neurological disorders (~10%)	0.2 million	\$31 billion	Cost of this health burden grew 15.6% between 2011-17	https://www.neura.edu.au/ news/new-report-reveals-the- australian-burden-of-disease- for-brain-disorders-is-almost- twice-the-global-figure
Mental health (~60%)	4.8 million	\$60 billion	COVID-19 has dramatically increased demand for mental health support services	https://www.aph.gov.au/ About_Parliament/ Parliamentary_Departments/ Parliamentary_Library/pubs/rp/ rp1819/Quick_Guides/ MentalHealth

Emyria

Care

We train and develop clinical experts



Dr Nelson Lau



Dr Jennifer Morgan



Dr Jennifer Tai



Dr Alistair Vickery



Dr David Gunn




Dr Phil Finch




Dr Ben Addison

Pictured: Some of Emyria's clinical team.

For more details on our care team, please visit **www.emyria.com**



* Under Australia's Therapeutic Goods Administration (TGA), psychedelic medications such as psilocybin and MDMA are currently Schedule 9 of the Uniform Scheduling of Medicines and Poisons (which deals with Prohibited Substances). They are only available via approved research trials that include oversight by an institutional research ethics committee and careful monitoring and reporting of efficacy and safety outcomes. There is an active rescheduling proposal before TGA so that they can be more easily used as clinical therapies for the treatment of mental illnesses. The rescheduling would move these medicines to Schedule 8 (which deals with Controlled Medicines), the same category as THC-containing cannabinoid medicines. For more information : <https://www.tga.gov.au/consultation-invitation/consultation-proposed-amendments-poisons-standard-acms-accs-and-joint-acmsaccs-meetings-november-2020>



Case Study – Bob



- Vietnam Veteran | injured by fall in 1969 | multiple fractures
- Chronic back pain | peripheral neuropathy from Agent Orange | PTSD
- **At initial visit:** oxycontin | buprenorphine | pregabalin | gabapentin | PEA duloxetine – with little relief and side effects.
- **Now:** Stable at 15mg 1:1 THC/CBD | **ceased all opiates**, pregabalin and PEA



Scores

Initial assessment


Visit 5

BPI Pain severity score	5.0	1.75
BPI Pain interference score	5.29	0.86
Visual analogue scale	5.0	1.0
Insomnia severity score	12.0	1.0
DASS 42 Depression	14	4
DASS 42 Anxiety	16	2
DASS 42 Stress	16	12

Growth story so far



Clinic locations across Australia
- **Perth, Melbourne, Sydney**



Feb

Mar

Apr

May

Jun

Jul

Aug

Sep

Oct



Nov

Next



Opened a **specialist clinic** for
mental health and **substance**
abuse in Northern NSW



2,000+
patients



Enter UK partnership with
Sapphire Medical - first
accredited medicinal
cannabis clinic in the UK.



3,000+
patients



*Further growth in
clinical services and
into **new treatment**
areas*

Emyria

Data

**Insights + services to
help developers obtain a
drug registration (i.e. a
“label claim”)**


indication-specific dose
response insights

strategic trial design

clinical trial execution

registration and
repurposing submission
support


Revenues from data & registration milestones






- **Emyria** approached in 2019 to develop a **pharmacovigilance** product registry for **largest cannabis company in the world**
- To include safety data for Australian patients taking Spectrum products seen through Emerald Clinics.
- After just 6 months, Emyria's PV services were expanded to include UK


**Total contract values
over \$1M (AUD)**



- **Emyria** approached in 2019 and provided insomnia-related outcome insights from Emyria's real-world data. These insights supported a Phase 2 trial.
- In parallel, Emyria conducted a home-based **Phase 1 clinical trial** via our national network - Emerald Clinics
- Emyria is now supporting registration strategies with insights and trial support for **multiple indications** in areas of major unmet need.




Growth story so far



Emyria's

digital health

**Emyria is investing in the
future of care**



Case Study - Openly



Openly

Health screening, powered by your **smartphone** and backed by a **clinical team**

- Mobile app **captures clinical vital signs** using just a Smartphone - **eg heart rate & heart rate variability** - important signs of physiological stress (*eg early signs of infection or mental health changes*)
- App also captures patient reported outcomes
- Partnership with Mt Sinai, largest hospital network in New York
- TGA registration as a “**Class 1 medical device**” (ARTG ID 343533)



Emyria's digital health platform


Simple, Scalable
Mobile-based supports large populations

Screening in Seconds
Easy to use screenings and objective clinical measurements


Actionable Insights
Aggregates population health data to manage risks

App

1.
Risks & Symptoms
Participants prompted by SMS, email or notification to complete a “**One Minute Daily Review**” of risk factors and symptoms



2.
Vital Signs
Vital sign information collected from everyone to improve objective clinical assessment




Control Centre

3.
Alerts
Evidence-based **risk scoring applied** based on patient inputs



4.
Clinical Screening
Clinical team monitors alerts and responds with direct tele-health consultation or coordinates referral to appropriate service



Status

Optional: Based on results, a ‘status’ and other educational information can be delivered to participants


Emyria's digital health technology improves value of data

Emyria positioned to rapidly bring new treatments to patients



Emyria's Digital Health Platform

- Additional TGA registrations as a medical device
- Develop technology partnerships to support strategy
- Use unique contactless vital sign technology to develop **digital biomarkers**



myriad data.
individual care.

Contact Information

Michael Winlo: mwinlo@emyria.com

Investors: investors@emyria.com

Media: media@emyria.com

General: info@emyria.com

ASX:EMD